Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Trial Details

NCT ID
NCT05702229
Phase
PHASE2
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • Rilvegostomig
  • Volrustomig
  • FOLFOX
  • XELOX
  • AZD0901
  • 5-Fluorouracil
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Baton Rouge, Louisiana, United States|30.44332,-91.18747
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • New Hyde Park, New York, United States|40.7351,-73.68791

Key Eligibility Criteria

  • 18 years or older at the time of signing the ICF.
  • Body weight \> 35 kg.
  • Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
  • Has measurable target disease assessed by the Investigator based on RECIST 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →